Delivery Order SPE2DB22D3016-SPE2DB25FBEW2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Havrix 720 Unit/0.5 ML syringes, with a ceiling value of $1,012.20 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of July 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,136.36 for 1,440 units/mL of HAVRIX vaccine syringes on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a single transaction under the company's larger pharmaceutical supply relationship...
- The Defense Logistics Agency awarded a $11,463.02 delivery order to AmerisourceBergen Drug Corp for 1,440 units/mL of HAVRIX vaccine syringes on July 28, 2025, with completion targeted for July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be...
- The Defense Logistics Agency awarded a $3,776.30 delivery order to AmerisourceBergen Drug Corp for Havrix 720 Unit/0.5 mL syringes on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract represents a pediatric hepatitis A vaccine delivery through AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract worth $8,753.04 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 4,563,981,944 units of the HAVRIX 720 Unit/0.5 ML syringe 0.5ML pharmaceutical product. The delivery order has an ultimate completion date of March 18, 2024. Amerisourcebergen Drug Corp, through its Corporate Office division in Conshohocken, Pennsylvania, is the prime contractor on this...
- The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a $1,567.92 firm fixed price delivery order to provide 4,563,580,840 units of the HAVRIX 720 0.5 ML syringe. This order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver pharmaceutical products and medical supplies to DLA...
- The Defense Logistics Agency has awarded a delivery order valued at $20,231.75 to AmerisourceBergen Drug Corp for the supply of 1,440 units/mL of HAVRIX vaccine in syringe form. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025, awarded on August 4, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Havrix 720 unit/0.5 mL syringes. The order has a firm fixed price of $3,440.70 and an ultimate completion date of June 4, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, that provides a comprehensive global pharmaceutical support vehicle with a...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HAVRIX 720 Unit/0.5 ML syringes, a vaccine product, with a total ceiling value of $1,012.20. The contract is a firm fixed-price, non-set-aside agreement with a performance period through May 7, 2025. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,012.20 to AmerisourceBergen Drug Corp for HAVRIX 720 Unit/0.5 ML syringes on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. HAVRIX is a hepatitis A vaccine product, reflecting the ongoing federal medical procurement needs for...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBEW2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Havrix 720 Unit/0.5 ML syringes valued at $5,671.48 with a firm fixed price structure. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support mechanism. The order is set for completion by August 14, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate headquarters and operates as a major pharmaceutical distributor supporting federal military and veteran healthcare systems. AmerisourceBergen Drug Corp's substantial IDC portfolio with the DLA reflects its established capability to deliver diverse pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare customers. The company's consistent receipt of competitively awarded, non-set-aside delivery orders demonstrates its ability to meet federal procurement requirements for critical medical commodities including vaccines, specialty medications, and branded and generic pharmaceuticals essential to military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.7k | 8/13/25 |